1. Home
  2. Press release
Jun 03, 2022 16:37 JST

Source: Eisai

Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting

TOKYO, Jun 03, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.

Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).

"DAYVIGO continues to serve as an important asset to Eisai's neurology portfolio and we look forward to presenting the findings from several analyses at this year's SLEEP Meeting," said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. "Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,(1),(2) and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs."

(1) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10

About Lemborexant (product name: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.

For more information, visit www.eisai.com/news/2022/news202244.html.

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
More Press release >>

Latest Press Release


ULVAC Establishes Japan-Based Production for Rare-Earth Magnet Vacuum Melting Furnaces
May 01, 2026 11:00 JST

teamLab Borderless Ranked Among the World's 100 Most Visited Art Museums and 4th in Japan
Apr 30, 2026 21:00 JST

TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST

NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
Apr 28, 2026 19:05 JST

Advancing Early Detection: OMRON Healthcare Supports May Measurement Month 2026
Apr 28, 2026 01:00 JST

NEC Announces Strategic Collaboration with Anthropic Focused on Enterprise AI
Apr 23, 2026 17:46 JST

Fujitsu and Carnegie Mellon University launch joint center for Physical AI
Apr 23, 2026 17:19 JST

China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank

Apr 22, 2026 21:32 JST

CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited
Apr 22, 2026 21:15 JST

OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC)
Apr 22, 2026 19:30 JST

MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK
Apr 22, 2026 17:16 JST

NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan
Apr 22, 2026 14:46 JST

MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kagoshima City

Apr 22, 2026 11:13 JST

MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Sendai City
Apr 22, 2026 11:03 JST

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST

Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST

BULL and Fujitsu Sign Basic Agreement to Develop Japan's Unique High-Precision Space Situational Awareness Service
Apr 21, 2026 11:47 JST

Fujitsu launches GLOVIA One ERP solution for mid-sized Japanese enterprises
Apr 20, 2026 11:46 JST

NEC to Supply Nine Types of Defense Equipment for Tthree Australian Frigates
Apr 19, 2026 12:10 JST

Mitani Sangyo Filed U.S. Patent Application for AI Reliability Governance Framework
Apr 17, 2026 00:00 JST
 More Latest Release >>